NCI Announces Funding Opportunity for Biospecimen Core
News Jul 16, 2015
The core will serve as a center for receiving, qualifying, processing, and distributing annotated biospecimens to the Clinical Proteomic Tumor Analysis Consortium (CPTAC).
CPTAC initiative has done protein biomarker discovery and verification studies in tumor tissue samples previously characterized at the genomic and transcriptomic level by the NCI's Cancer Genome Atlas (TCGA) team. In the first phase of the project, participating researchers undertook analysis of three tumor types — breast, colorectal, and ovarian.
In the next phase the project aims to extend their analysis to additional cancer types. According to the agency, this work will require the acquisition of high-quality, clinically annotated, primary, and untreated tumor specimens from patients with specific cancer types.
Tissue Source Sites will prospectively collect samples consisting of primary human tumors, blood, and non-malignant tissue according to protocols optimized for proteomics, which will then be passed on to the Biospecimen Core Resource.
Prostate- and Colon Cancer Targeted With Tapeworm DrugNews
Recently researchers found that a substance in medicine against parasites like Giardia and Tapeworms, acts like tailored medicine against prostate- and colon cancer.READ MORE
New Player in Alzheimer's Disease Pathogenesis IdentifiedNews
Using proteomics, microscopic analysis, and functional assays, scientists have shown that a protein called membralin is critical for keeping Alzheimer’s disease pathology in check.READ MORE
Proteome of the Human Heart Mapped for the First TimeNews
Scientists have determined which and how many individual proteins are present in each type of cell that occurs in the heart. In doing so, they compiled the first atlas of the healthy human heart, known as the cardiac proteome. The atlas will make it easier to identify differences between healthy and diseased hearts in future.READ MORE